Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Source filing unavailable
Q1 2015 · —
Revenue$7.59B$7.59B+51.9% vs Q1 2014 Net Income$4.33B$4.33B+94.6% vs Q1 2014 EPS Diluted$2.76$2.76+107.5% vs Q1 2014 Gross Profit$6,523,000,000+60.7% Operating Income$5,371,000,000+76.5% Operating Cash Flow$5,701,000,000
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
+263.6%
Free Cash Flowderived$5,577,000,000+297.2% Margins · derivedGross margin85.9%+4.7 pt vs Q1 2014
Operating margin70.7%+9.9 pt vs Q1 2014
Net margin57.1%+12.5 pt vs Q1 2014